Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
ORLANDO — In this video, Jay S. Duker, MD, president and CEO of EyePoint Pharmaceuticals, discusses preclinical data on vorolanib presented at Eyecelerator@AAO.
“We’ve always known that vorolanib was a potent inhibitor of all the VEGF receptors,” Duker said. “What we’ve now discovered is we also have an anti-inflammatory component to vorolanib.”
Duker explained that “with this essentially bispecific approach of blocking both VEGF and inflammation, we are especially confident in the results of our clinical trial.”